Digital health company Verana Health (San Francisco) has unveiled the Qdata anti-VEGF market tracker. It is their first market tracking Data as a Service (DaaS) product.
Excessive amounts of vascular endothelial growth factor (VEGF) can cause abnormal blood vessel growth in the eyes, which, when untreated, can result in vision loss in patients with retinal diseases. Consequently, anti-VEGF therapies help preserve eyesight for patients with conditions such as age-related macular degeneration and diabetic retinopathy.Qdata anti-VEGF market tracker supports brand-level analysis
The Qdata anti-VEGF market tracker enables comprehensive brand-level analysis. It also provides direct access to real-world data, according to Sujay Jadhav, Verana Health’s CEO. The service offers accurate and timely insights into product performance and market dynamics.
Real-world data is drawn from the Ameri…